Changes in BMI and Management of Patients with Childhood Onset Growth Hormone Deficiency in the Transition Phase

M. Á. Bazarra-Castro; C. Sievers; H. P. Schwarz; S.B.-D. Pozza; G. K. Stalla

doi:10.1055/s-0032-1327599

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2012; 120(09): 507-510
DOI: 10.1055/s-0032-1327599

Article

Changes in BMI and Management of Patients with Childhood Onset Growth Hormone Deficiency in the Transition Phase

M. Á. Bazarra-Castro

¹Endocrinology and Clinical Chemistry, Department of Internal Medicine, Max Planck Institute of Psychiatry, Munich, Germany

,

C. Sievers

¹Endocrinology and Clinical Chemistry, Department of Internal Medicine, Max Planck Institute of Psychiatry, Munich, Germany

,

H. P. Schwarz

²Division of Endocrinology and Diabetology, University Children’s Hospital, Dr. von Haunersches Kinderspital der Ludwig-Maximilians Universität, Munich, Germany

,

S.B.-D. Pozza

²Division of Endocrinology and Diabetology, University Children’s Hospital, Dr. von Haunersches Kinderspital der Ludwig-Maximilians Universität, Munich, Germany

,

G. K. Stalla

¹Endocrinology and Clinical Chemistry, Department of Internal Medicine, Max Planck Institute of Psychiatry, Munich, Germany

› Author Affiliations

Abstract

Objective:

We aimed at evaluating BMI changes during GH therapy pause, to assess the transfer pattern between children and adult medical services in our clinic and to confirm the previous growth hormone deficiency (GHD) diagnosis.

Design:

Retrospective cohort study.

Methods:

We identified 75 transition patients (age at first visit <25 years) with pituitary deficiency (ICD-10:E.23) and GHD referred to our clinic between 2000–2009.

Results:

Out of 75 patients with GHD (45 males, 30 females), 20 subjects suffered from an idiopathic GHD (iGHD) and 55 from an organic GHD (oGHD). During the GH therapy pause (26.4±34.8 months), we observed a significant BMI increase (23.6±4.4 to 27.1±7.2, p=0.02). Most males with iGHD discontinued endocrinologic control and GH substitution completely (5 patients out of 20) or after the first contact (3 patients out of 20). Most females with GHD continued medical control after transferral (22 patients). We retested 34/75 patients with GHD (45.3%). The preferred test was the growth hormone-releasing hormone-arginine (GHRH-arginine) (20/34 patients, 58.9%), followed by the insulin hypoglycemia test (IHT) alone (9 patients). 4 patients received both, the GHRH-arginine and the IHT. Seven retested patients with iGHD (63.6%) and all oGHD retested patients were still deficient.

Conclusions:

Our results provide information on negative effects of the discontinuation of GH treatment during the transition phase and should help to improve the compliance with treatment in this group of patients. Paediatric and adult endocrinologists participating together in a transition programme should emphasize on the positive effect of GH substitution in adulthood. Efforts should be made to particularly improve the transferral of male adolescents with iGHD, since they seem to escape medical care.

Key words

hypopituitarism - pituitary adenoma - obesity

Full Text

References

References
1 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83 (02) 379-381
2 Atanasio AF, Howell S, Bates PC et al Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab 2002; 87 (07) 3368-3372
3 Biller BM, Samuels MH, Zagar A et al Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002; 87 (05) 2067-2079
4 Clayton PE, Cuneo RC, Juul A et al European Society of Pediatric Endocrinology Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005; 152 (02) 165-170
5 Drake WM, Carroll PV, Maher KT et al The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003; 88 (04) 1658-1663
6 Flegal KM, Troiano RP. Changes in the distribution of body mass index of adults and children in the US population. Int J Obes Relat Metab Disord 2000; 24 (07) 807-818
7 Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007; 157 (06) 695-700
8 Hulthén L, Bengtsson BA, Sunnerhagen KS et al GH is needed for the maturation of muscle mass and strength in adolescents. J Clin Endocrinol Metab 2001; 86 (10) 4765-4770
9 Johannsson G, Albertsonn-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999; 84 (12) 4516-4524
10 Nguyen VT, Misra M. Transitioning of children with GH deficiency to adult dosing: changes in body composition. Pituitary 2009; 12 (02) 125-135
11 Radovick S, DiVall S. Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 2007; 92 (04) 1195-1200
12 Rosenfeld RG, Bakker B. Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008; 14 (02) 143-154
13 Savage MO, Drake WM, Carroll PV et al Transitional care of GH deficiency: when to stop GH therapy. Eur J Endocrinol 2004; 151 (Suppl. 01) S61-S65